ADAMTS13 and hemolytic-uremic syndrome: Our previous study demonstrated that serum ADAMTS-13 activity was significantly lower in patients with both LN and TTP-HUS than in patients with LN only (40% versus 69%, p = 0.012) and in normal control (40% versus 81%, p < 0.001).